tozorakimab   Click here for help

GtoPdb Ligand ID: 12964

Synonyms: MEDI-3506 | MEDI3506
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tozorakimab (MEDI3506) is a high-affinity anti-IL-33 monoclonal antibody. It inhibits IL-33-induced signalling to produce an anti-inflammatory effect [2]. Tozorakimab blocks the actions of both reduced IL-33 (IL-33red) and oxidized IL-33 (IL-33ox) metabolites through their respective downstream pathways (ST2 for IL-33red, RAGE/EGFR complex for IL-33ox) [1,3-4].
No information available.
Summary of Clinical Use Click here for help
Tozorakimab (MEDI3506) was advanced to clinical studies for inflammatory conditions including asthma, chronic obstructive pulmonary disease and atopic dermatitis. Tozorakimab was one of the original clinical candidates to be included in the ACCORD COVID-19 study [5].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04212169 Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis Phase 2 Interventional AstraZeneca
NCT04570657 Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma Phase 2 Interventional AstraZeneca
NCT04631016 A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis Phase 2 Interventional AstraZeneca
NCT06040086 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Phase 3 Interventional AstraZeneca
NCT05742802 Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations. Phase 3 Interventional AstraZeneca
NCT05624450 Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen Phase 3 Interventional AstraZeneca